Tejara Capital Ltd lessened its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 42.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 813,550 shares of the company's stock after selling 607,440 shares during the period. Roivant Sciences comprises 6.2% of Tejara Capital Ltd's portfolio, making the stock its 2nd largest position. Tejara Capital Ltd owned 0.11% of Roivant Sciences worth $9,624,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the company. US Bancorp DE raised its position in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock worth $38,000 after purchasing an additional 1,948 shares during the period. GAMMA Investing LLC raised its position in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after purchasing an additional 1,288 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after purchasing an additional 1,507 shares during the period. Quarry LP raised its position in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company's stock worth $87,000 after purchasing an additional 2,500 shares during the period. Finally, Blue Trust Inc. raised its position in shares of Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock worth $91,000 after purchasing an additional 6,667 shares during the period. Institutional investors own 64.76% of the company's stock.
Analyst Ratings Changes
ROIV has been the topic of a number of research reports. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Roivant Sciences presently has a consensus rating of "Buy" and an average price target of $18.08.
Check Out Our Latest Stock Analysis on ROIV
Roivant Sciences Stock Performance
Shares of ROIV stock traded down $0.18 during mid-day trading on Friday, hitting $10.79. 15,739,544 shares of the stock traded hands, compared to its average volume of 5,623,817. Roivant Sciences Ltd. has a twelve month low of $9.93 and a twelve month high of $13.06. The firm has a market cap of $7.70 billion, a price-to-earnings ratio of -71.93 and a beta of 1.26. The company's 50-day simple moving average is $10.78 and its 200-day simple moving average is $11.47.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Insider Activity
In other news, CIO Mayukh Sukhatme sold 185,946 shares of the firm's stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total transaction of $2,231,352.00. Following the completion of the sale, the executive now directly owns 18,836,547 shares of the company's stock, valued at $226,038,564. This trade represents a 0.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Eric Venker sold 177,704 shares of the firm's stock in a transaction on Monday, December 30th. The stock was sold at an average price of $11.54, for a total value of $2,050,704.16. Following the sale, the chief operating officer now directly owns 740,976 shares of the company's stock, valued at approximately $8,550,863.04. This represents a 19.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,875,586 shares of company stock worth $21,491,661. 7.90% of the stock is owned by company insiders.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
